HCC44 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Lung cancer cell lines |
| Organism |
Human |
| Donor History |
Adenocarcinoma |
| Growth Properties |
Adherent |
| Growth Conditions |
Culture medium: RPMI 1640 ,w: 2.0 mM stable Glutamine ,w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Seeding density: 1 to 3 x 10⁴ cells/cm². Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
The HCC44 cell line is a non-small cell lung cancer (NSCLC) model known for harboring a KRAS mutation, which plays a significant role in cancer progression and treatment resistance. In a study exploring the characteristics of KRAS-driven NSCLC, HCC44 was identified as dependent on malic enzyme 1 (ME1) for viability, suggesting that the KRAS mutation in this cell line enhances the expression of genes involved in glutamine metabolism and redox balance. ME1’s role in generating NADPH aids in countering oxidative stress, which is particularly vital for KRAS-mutant cancer cells undergoing rapid proliferation.
Further research into natural compounds like chromomycin analogs has shown potential therapeutic relevance to HCC44. Chromomycin SA2 and related molecules were evaluated for their cytotoxic effects on HCC44, showing reduced potency compared to other analogs due to modifications in side chains that affect their interaction with DNA. Additionally, the cell line’s response to radiation therapy has been studied, indicating that perturbing glutamine metabolism could sensitize HCC44 to radiation, potentially overcoming some aspects of radioresistance conferred by KRAS mutations.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

